Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GM3 ganglioside is a sialic acid-containing glycosphingolipid, classified as a ganglioside. Structurally, it consists of a ceramide lipid anchor, a lactose unit, and a terminal sialic acid; it is the simplest member of the ganglioside family and acts as the biosynthetic precursor to more complex gangliosides[1][5][7][8]. GM3 is a key component of the plasma membrane in many cell types, notably neural and immune tissues, and organizes into membrane microdomains known as lipid rafts or caveolae[5][7]. It modulates cell signaling, influencing processes like cell growth, apoptosis, immune responses, and myelin formation[3][5][7][8]. GM3's roles in pathophysiology include being a mediator and a potential therapeutic target in cancer (where it inhibits proliferation and tumor growth), autoimmunity (functioning as an autoantigen in neuropathies), metabolic diseases (modulating insulin and inflammatory signaling), and demyelinating disorders[3][4][5][7][9]. The diversity of its biological effects relates both to its structural variants (which affect fatty acid and sphingosine composition) and to its cellular context. GM3 is considered a therapeutic target for cancer and metabolic disease, though safety concerns arise from its critical physiological functions and wide tissue distribution[1][3][5][7][9]. Caveats: - There are no well-established, widely approved drugs targeting GM3 directly in clinical use; most data on interacting drugs and biomarkers is preclinical or from mechanistic studies. - GM3 is not a protein but a lipid; while frequently regarded as a "target" in the sense of immunological and pharmacological modulation, its biochemistry is distinct from receptor/drug paradigms typical for proteins.
Promotion of apoptosis through GM3 enrichment/cell signaling modulation (e.g., by cisplatin)[7]; Inhibition of growth factor receptor activity and cytokine production via plasma membrane effects[7][5]; Modulation of Toll-like receptor 4 (TLR4) signaling (pro- and anti-inflammatory effects depend on GM3 species)[4][9]; Disruption/modulation of glucose uptake via insulin receptor and caveolar interactions[5]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GM3 ganglioside (GM3).